Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immutep Ltd ADR (NQ: IMMP )

2.650 +0.050 (+1.92%)
Streaming Delayed Price Updated: 1:24 PM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 130,769
Open 2.730
Bid (Size) 2.650 (5)
Ask (Size) 2.670 (3)
Prev. Close 2.600
Today's Range 2.600 - 2.740
52wk Range 1.500 - 3.900
Shares Outstanding 748,152,935
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients without PD-L1 expression. Final data expected in H1 CY2024. 
Via Benzinga

Performance

YTD
+12.77%
+12.77%
1 Month
+8.16%
+8.16%
3 Month
+22.12%
+22.12%
6 Month
+41.71%
+41.71%
1 Year
+60.61%
+60.61%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
From Immutep Limited
Via GlobeNewswire
Cancer Focused Immutep's Stock Soars On Tuesday - Here's Why
Via Benzinga
Immutep Touts Encouraging Data From Efti Triple Combination Therapy In Lung Cancer Setting
Via Benzinga
Maxim Group Maintains Buy Rating for Immutep: Here's What You Need To Know
Via Benzinga
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
From Immutep Limited
Via GlobeNewswire
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
7 Stocks That Could Triple Your Money by 2024
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2023
Via Benzinga
3 Best Penny Stocks Under $3 to Buy in June
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Immutep Shares Spike As Cancer Tratement Shows Favorable Results In Phase 2 Trial
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
From Immutep Limited
Via GlobeNewswire
7 Best Penny Stocks Under $3 to Buy in April
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Why Did Immutep Ltd Stock Soar Recently?
Via MarketBeat
Topics Initial Public Offering
Exposures Product Safety Securities Market
Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
From Immutep Limited
Via GlobeNewswire
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
From Immutep Limited
Via GlobeNewswire
Why AeroClean Technologies Is Trading Higher By Over 39%; Here Are 26 Stocks Moving Premarket
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.